SomaSignal™ Tests turn proteomic data into clinical metrics for diabetes
18 clinical metrics from 55µl blood, including:
- Glucose Tolerance
- Resting energy
- Visceral fat
- Cardiorespiratory fitness
- Alcohol impact
- Heart failure
Ideal for clinical trial monitoring
- Assess comorbidities, including fatty liver and heart disease
- Measure VO2 max without an exercise test
- Determine drug efficacy
- Identify at-risk patients
- Identify patients likely to respond
The SomaScan proteomic platform has been used extensively to discover and characterize protein signatures of heart health. There are more than 25 publications collating thousands of protein measurements across thousands of patients with heart health. Using millions of data points, machine learning models were developed that can simultaneously measure multiple clinically relevant metrics relating to CVD.
The SomaSignal tests turn massive scale proteomics into clinically significant metrics for heart health. Multiple SomaSignal tests can be run on the same sample, enabling the determination of primary cardiovascular risk, secondary cardiovascular risk, pulmonary fitness, heart failure risk, and more, all from a single 55 µl blood sample. Straightforward and thorough reporting (survival probability, percent risk, risk categories, VO2 max, and qualitative fitness levels) simplifies the analysis process, so that outcomes can quickly be reported for assessment in clinical trials.
Additional somasignal tests
The CVD, heart failure, and cardiorespiratory fiitness tests make up a subset of 18 SomaSignal tests available for research use. Any or all of the SomaSignal tests are available for a single flat cost.
The statements herein have not been evaluated by the Food and Drug Administration